IQVIA (NYSE:IQV) Upgraded to “Buy” at StockNews.com

IQVIA (NYSE:IQV) was upgraded by investment analysts at StockNews.com from a “hold” rating to a “buy” rating in a research note issued to investors on Monday.

Other analysts have also issued research reports about the company. Morgan Stanley upped their price objective on IQVIA from $270.00 to $280.00 and gave the company an “overweight” rating in a research note on Tuesday, July 23rd. Truist Financial lowered their price objective on IQVIA from $300.00 to $286.00 and set a “buy” rating on the stock in a research report on Monday. Argus raised shares of IQVIA to a “strong-buy” rating in a report on Wednesday, July 31st. Evercore ISI reduced their price target on IQVIA from $270.00 to $265.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th. Finally, Robert W. Baird upped their target price on IQVIA from $251.00 to $256.00 and gave the company a “neutral” rating in a research report on Friday, September 20th. Four analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $268.87.

IQVIA Trading Up 1.7 %

IQV traded up $3.96 during mid-day trading on Monday, reaching $233.22. The stock had a trading volume of 683,064 shares, compared to its average volume of 1,069,485. The firm’s fifty day simple moving average is $239.15 and its two-hundred day simple moving average is $231.46. The company has a debt-to-equity ratio of 1.80, a quick ratio of 0.85 and a current ratio of 0.85. The stock has a market capitalization of $42.49 billion, a P/E ratio of 31.86, a P/E/G ratio of 2.18 and a beta of 1.49. IQVIA has a 52 week low of $167.42 and a 52 week high of $261.73.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Monday, July 22nd. The medical research company reported $2.64 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.57 by $0.07. The business had revenue of $3.81 billion for the quarter, compared to analyst estimates of $3.79 billion. IQVIA had a return on equity of 28.59% and a net margin of 9.39%. The firm’s revenue was up 2.3% on a year-over-year basis. During the same period last year, the company earned $2.22 EPS. On average, equities analysts predict that IQVIA will post 10.25 EPS for the current year.

Insider Buying and Selling

In related news, insider Eric Sherbet sold 1,300 shares of the stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total transaction of $320,229.00. Following the transaction, the insider now directly owns 19,536 shares of the company’s stock, valued at $4,812,302.88. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.60% of the stock is currently owned by insiders.

Institutional Investors Weigh In On IQVIA

A number of hedge funds have recently added to or reduced their stakes in IQV. First Foundation Advisors grew its holdings in shares of IQVIA by 3.8% during the second quarter. First Foundation Advisors now owns 1,161 shares of the medical research company’s stock valued at $245,000 after buying an additional 43 shares during the last quarter. Team Hewins LLC raised its holdings in shares of IQVIA by 5.0% in the first quarter. Team Hewins LLC now owns 973 shares of the medical research company’s stock valued at $246,000 after purchasing an additional 46 shares during the last quarter. Invera Wealth Advisors LLC lifted its position in shares of IQVIA by 0.3% during the second quarter. Invera Wealth Advisors LLC now owns 14,506 shares of the medical research company’s stock valued at $3,183,000 after purchasing an additional 46 shares in the last quarter. Covestor Ltd grew its position in IQVIA by 45.3% in the 1st quarter. Covestor Ltd now owns 154 shares of the medical research company’s stock worth $39,000 after purchasing an additional 48 shares in the last quarter. Finally, Oregon Public Employees Retirement Fund lifted its position in shares of IQVIA by 0.3% during the 2nd quarter. Oregon Public Employees Retirement Fund now owns 15,668 shares of the medical research company’s stock worth $3,313,000 after buying an additional 48 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.